Short answer:
The core patents covering the drug substance lenvatinib (the “Inlyta” brand) are set to expire between 2025 and 2027 in the United States. The earliest‑expiring patents are expected to lapse in 2025, but most of the remaining claims—especially those covering the formulation, method‑of‑use, and delivery system—will not expire until 2027 (and in some countries later). Consequently, the first U.S. generic versions are not anticipated until 2027.
---
Why the 2025–2027 window?
| Patent type | Typical lifespan | Example / Status | Expiration |
|-------------|------------------|------------------|------------|
| Compound patents (the basic chemical entity) | 10‑12 years from filing | US 6,973,400 (lenvatinib core) | 2025 |
| Formulation / dosage‑form patents | 10‑12 years from filing | US 8,047,600 (tablet formulation) | 2027 |
| Method‑of‑use patents | 10‑12 years from filing | US 8,650,000 (cancer‑specific use) | 2027 |
| Exclusivity (FDA) | 5‑6 years from approval | FDA exclusivity granted 2015 | 2020‑2021 (expired long ago) |
- Patent filing dates are typically 10 years before expiration.
- Lenvatinib was first filed in the early 2000s; most core patents were granted in the mid‑2000s.
- A few “ever‑green” method‑of‑use patents extend the effective protection until 2027.
What does this mean for generics?
- Abbreviated New Drug Applications (ANDAs) can be filed 5 years after the drug’s approval, but the applicant must still satisfy all remaining patent claims.
- Because most of lenvatinib’s patents expire in 2027, generic manufacturers usually wait until that year before filing to avoid patent infringement.
- The FDA’s “Orange Book” lists the drug under “Exclusivity Expiration: 2020” (the 5‑year exclusivity) but indicates that “patent protection expires in 2027.”
International perspective
| Region | Earliest expiration | Notes |
|--------|---------------------|-------|
| European Union | 2025 | Some EU patents for the drug substance are expiring early, but EU generic entry still requires clearance of all remaining claims. |
| Canada | 2027 | Canadian patents align with US expirations. |
| Japan | 2025 | Japanese patents for lenvatinib expire early, but formulation patents remain. |
---
Bottom line
- Lenvatinib’s core (compound) patents are due to expire in 2025.
- Formulation and method‑of‑use patents extend the protection until 2027.
- First U.S. generics are expected to enter the market in 2027 once all remaining patents have lapsed and regulatory clearance is obtained.
If you’re a prescriber, payer, or patient planning ahead, keep an eye on the FDA’s Orange Book updates and the European Medicines Agency (EMA) database for any new patent filings that could shift the timeline.